IP Library Granted Patent US 7,914,811
Granted Patent B2
US 7,914,811 · App. 09/896,052 · Granted Mar 29, 2011

Brittle-coating, soft core dosage form

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,914,811
App. No.
09/896,052
Granted
Mar 29, 2011
Kind
B2
Abstract

The present invention provides an oral dosage form for delivering active agents having a soft core with an active agent particles, which have an average size of greater than about 50 μm, and a brittle shell encasing the soft core, wherein the weight ratio of drug particles to shell being from about 1.0:0.5 to about 1.0:15.

Claims (20)

1. A texture masking oral dosage form comprising:

(a) a unitary molded soft core comprising a plurality of active agent particles having an average size of from about 150 μm to about 500 μm, a hydrocolloid, and water; wherein the active agent particles have a gritty texture and

(b) a soft panned brittle shell encasing the soft core in an amount of from about 20% to about 50% of the total weight of the texture masking oral dosage form and a thickness of from about 500 μm to about 3000 μm, wherein the weight ratio of active agent particles to shell is from about 1.0:0.5 to about 1.0:15 in the texture masking oral dosage form and wherein the soft core is pectin or gelatin based.

2. An oral dosage form of claim 1 , wherein the weight ratio of active agent particles to shell is from about 1.0:2 to about 1.0:12.

3. An oral dosage form of claim 2 , wherein the weight ratio of particles to shell is from about 1.0:4 to about 1.0:9.

4. An oral dosage form of claim 1 , wherein the active agent is selected from the group consisting of acetaminophen, ibuprofen, pseudoephedrine, dextromethorphan, diphenhydramine, chlorpheniramine, calcium carbonate, magnesium hydroxide, magnesium carbonate, magnesium oxide, aluminum hydroxide, mixtures thereof, and pharmaceutically acceptable salts thereof.

5. An oral dosage form of claim 4 , wherein the active agent is acetaminophen or ibuprofen.

6. An oral dosage form of claim 5 , wherein the active agent is acetaminophen.

7. An oral dosage form of claim 5 , wherein the active agent is ibuprofen.

8. An oral dosage form of claim 3 , wherein the active agent is selected from the group consisting of acetaminophen, ibuprofen, pseudoephedrine, dextromethorphan, diphenhydramine, chlorpheniramine, calcium carbonate, magnesium hydroxide, magnesium carbonate, magnesium oxide, aluminum hydroxide, mixtures thereof, and pharmaceutically acceptable salts thereof.

9. An oral dosage form of claim 8 , wherein the active agent is acetaminophen or ibuprofen.

10. An oral dosage form of claim 9 , wherein the active agent is acetaminophen.

11. An oral dosage form of claim 9 , wherein the active agent is ibuprofen.

12. A texture masking oral dosage form comprising:

(a) a unitary molded soft core comprising a plurality of acetaminophen particles having an average size of from about 150 μm to about 500 μm, a hydrocolloid, and water; wherein the acetaminophen particles have a gritty texture and

(b) a soft panned brittle shell enveloping the soft core in an amount of from about 20% to about 50% of the total weight of the texture masking oral dosage form and a thickness of from about 500 μm to about 3000 μm, wherein the weight ratio of active agent to shell is from about 1.0:4 to about 1.0:9 in the texture masking oral dosage form and wherein the soft core is pectin or gelatin based.

13. A texture masking oral dosage form comprising:

(a) a unitary molded soft core comprising a plurality of ibuprofen particles having an average size of from about 150 μm to about 500 μm, a hydrocolloid, and water; wherein the ibuprofen particles have a gritty texture and

(b) a soft panned brittle shell enveloping the soft core in an amount of from about 20% to about 50% of the total weight of the texture masking oral dosage form and a thickness of from about 500 μm an to about 3000 μm, wherein the weight ratio of particles to shell is from about 1.0:4 to about 1.0:9 in the texture masking oral dosage form and wherein the soft core is pectin or gelatin based.

14. The dosage form of claim 1 , wherein the unitary molded soft core is formed in a starch mold, a sugar mold, or a brittle mold.

Assignments (4)
MERGER Recorded Jan 27, 2022
From: CHENANGO ZERO LLC
To: CHENANGO TWO LLC
Reel/Frame 058888/0133 →
MERGER AND CHANGE OF NAME Recorded Jan 27, 2022
From: CHENANGO TWO LLC; CURRAHEE HOLDING COMPANY INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 058888/0210 →
MERGER Recorded Jan 27, 2022
From: JOHNSON & JOHNSON CONSUMER INC.
To: CHENANGO ZERO LLC
Reel/Frame 059618/0521 →
MERGER AND CHANGE OF NAME Recorded Jul 2, 2015
From: MCNEIL-PPC, INC.; JOHNSON & JOHNSON CONSUMER INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 036049/0254 →